Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.



PPMI Enrollment Status

95%
Genetic Cohort Participants
Enrollment Goal: 600

79%
Genetic Registry Participants
Enrollment Goal: ~600

100%
De Novo PD Participants
Enrollment: 424

100%
Control Participants
Enrollment: 196

100%
Subjects with SWEDD
Enrollment: 64

100%
Prodromal Participants
Enrollment: 65

Last Update: May 21 2018

 

More about study cohorts >

A Landmark Study of Parkinson’s Disease

The Parkinson?s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson?s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson?s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson?s Research.

Learn more about Who We Are.

LATEST NEWS FROM PPMI

PPMI Study Update Call – 6/14/18

PPMI Study Update Call Cerebrospinal Fluid Analysis Thursday, June 14 12-1 pm Eastern Time Brit Mollenhauer, MD Attending Neurologist, Head of Clinical Research PPMI Steering Committee Member Paracelsus-Elena Klinik Doug Galasko, MD Professor of Neurology PPMI Steering Committee Member University of California San Diego   PPMI participants are encouraged to call in to the next […]


2018 PPMI Annual Meeting Summary

The 2018 PPMI Annual Investigator’s Meeting took place on May 2-3 in New York City.  There were more than 200 attendees present, including PPMI investigators and coordinators, Industry Scientific Advisory Board representatives, The Edmond J. Safra Fellowship in Movement Disorders fellows and fellowship directors, the PPMI Patient Committee, and the PPMI Steering Committee. This meeting […]


Collaboration with Verily Aims to Deepen Parkinson’s Understanding through Digital Health Tools

Wearable sensors to monitor health-related measures like heart rate, glucose levels, or physical activity are helping people assess their own health and enabling research in treating and understanding chronic disease. The Michael J. Fox Foundation (MJFF) and Verily Life Sciences LLC, an Alphabet company, are collaborating to use wearable devices — in conjunction with clinic-based data and […]


PPMI Steering Committee Paper Accepted to Movement Disorders Journal

We are excited to announce a recent research article using longitudinal data from PPMI has been accepted to Movement Disorders.  Members of the PPMI Steering Committee, including Dr. Tanya Simuni of Northwestern University, authored this publication on behalf of PPMI. The study, entitled “Longitudinal Change of Clinical and Biological Measures in Early Parkinson’s Disease: Parkinson’s […]


PPMI Study Update Call – 3/15/18

PPMI Study Update Call Thursday, March 15 12-1 pm Eastern Time Andrew Siderowf, MD, MSCE Professor of Neurology University of Pennsylvania Co-Principal Investigator of PPMI   PPMI participants are encouraged to call in to the next quarterly Study Update Call on Thursday, March 15, 2018 at 12 pm EST.  During this call, Dr. Andrew Siderowf, […]


Learn More